Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M204665200 on May 24, 2002

J. Biol. Chem., Vol. 277, Issue 33, 29953-29962, August 16, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/33/29953    most recent
M204665200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, L.
Right arrow Articles by Kanwar, Y. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, L.
Right arrow Articles by Kanwar, Y. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Isolation and Functional Analysis of Mouse UbA52 Gene and Its Relevance to Diabetic Nephropathy*

Lin SunDagger , Xiaomin PanDagger , Jun Wada§, Christian S. HaasDagger , Rudolf P. WuthrichDagger , Farhad R. Danesh, Sumant S. Chugh, and Yashpal S. KanwarDagger ||

From the Departments of Dagger  Pathology and  Medicine, Northwestern University Medical School, Chicago, Illinois 60611 and the § Department of Medicine, Okayama University, Okayama 700-8558, Japan

Received for publication, May 13, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In delineating the mechanism(s) of diabetic nephropathy various novel genes have been isolated, whereas others remain to be discovered. We identified several up-regulated genes in the kidneys of diabetic newborn mice. Among them was UbA52, a ubiquitin ribosomal fusion protein. Its mRNA expression in the kidney was proportional to blood glucose levels. By in situ hybridization and immunohistochemistry, UbA52 was exclusively localized to renal tubules, and its expression was markedly increased in diabetic mice. The up-regulated UbA52 mRNA and protein expression were also observed in Madin-Darby canine kidney cells, a tubular cell line, treated with 30 mM glucose in both cell lysates and ribosomal fractions. To explore the mechanism(s) of its increased expression, UbA52 genomic DNA was isolated. A transcription start site at -22 bp from the initiation codon was identified and confirmed by primer extension analysis. The UbA52 promoter region included glucose response-related E-box sequences and stress response elements (STRE). Unlike in humans, mouse UbA52 gene had no introns in the coding or 5'-ATG-flanking regions. To identify the DNA segment with maximal promoter activity, deletion constructs were prepared using a pSEAP vector system and transfected into COS7 kidney cells. Maximal activity was confined to -198 to +68 bp, which included E-boxes and STRE motifs. A dose-dependent increase in the promoter activity was observed in cells exposed to high glucose. Mutations in the first E-box (CAGCTG right-arrow TGGCTG) or STRE (CCCCT right-arrow CATCT) resulted in a decrease in the SEAP activity under high glucose ambience. Given the presence of glucose-responsive motifs in the promoter region and decrease in the SEAP activity in E-box mutants in the presence of glucose, these data suggest that UbA52, a ribosomal fusion protein, may be relevant in the pathogenesis of diabetic nephropathy.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Diabetic nephropathy is the most common cause of end stage renal disease in the United States. It is characterized by thickening of basement membranes and mesangial expansion with progression into glomerulosclerosis, tubular atrophy, and interstitial fibrosis, ultimately resulting in renal failure (1). A wide variety of mechanisms in the pathogenesis of diabetic nephropathy have been proposed. They include accumulation of nonenzymatic glycated end products in the kidney, oxidation of renal glycoproteins by reactive oxygen species, intracellular accumulation of sorbitol generated by the reduction of glucose by aldose reductase, activation of protein kinase C-diacylglycerol pathway, involvement of mitogen-activated protein kinase and growth factors, e.g. insulin-like growth factor and transforming growth factor-beta , and alterations in renal hemodynamics (2-7). Involvement of such diverse mechanisms would indicate that a vast number of molecules and different signal transduction pathways are involved in its pathogenesis. In this regard, newer molecules exhibiting a transcriptional response to hyperglycemia are being discovered at a rapid pace during the last decade, and their identification has given new insights in the pathogenesis of diabetic nephropathy. The identification of these molecules has been facilitated by the use of various molecular biology techniques that employ the isolation of differentially expressed genes in the hyperglycemic versus the normoglycemic state. Such techniques include gene discovery array, representational difference analysis of cDNA, traditional subtractive or differential hybridization, and differential display (8). The use of these techniques has led to the successful isolation of several known human and mouse genes as well as the unknown genes available in the expressed sequence tag mouse or human NCBI data base. Most of these methods are not well suited for the identification of rare messages because they require large amounts of mRNA. Moreover, if the amount of mRNA is limited, it would require several rounds of amplification and hybridization, resulting in false positive signals. More recently, subtraction suppression hybridization-PCR (SSH-PCR)1 (CLONTECH), a procedure based on the selective amplification of differentially expressed genes in response to a given experimental stimulus, has become available, and it equalizes for the relative abundance of cDNAs within a target population and minimizes the false identification of irrelevant genes.

Utilizing SSH-PCR procedure, nine differentially expressed genes from the kidneys of newborn diabetic mice were isolated. Among them was UbA52, a ubiquitin fusion protein. UbA52, a 128-amino acid fusion protein, is made up of a 52-amino acid 60 S ribosomal protein attached to a 76-amino acid ubiquitin peptide (9). The ubiquitin is highly conserved in various species and is generated in cells by proteolysis of larger proteins containing either polyubiquitin chains or ubiquitin fused to carboxyl extension proteins. In humans, two ubiquitin-carboxyl extension protein genes, UbA80 and UbA52, code for ubiquitin fused to ribosomal proteins S27a and L40, respectively (9). The relevance of ubiquitin in muscle wasting in diabetes is known, and activation of ubiquitin-proteosome system has been well described in the literature (10). However, the relevance of ubiquitin or the ubiquitin fusion protein UbA52 in diabetic nephropathy remains to be investigated. This paper describes the isolation of mouse UbA52 gene, its expression in the kidneys of diabetic mice, and characterization of some of the molecular features of its promoter region that may be relevant in the pathogenesis of diabetic nephropathy.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Animals and Induction of Diabetes-- A hyperglycemic state was induced in pregnant female ICR mice (Harlan Co.) on day 13 of gestation by injection of streptozotocin (200 mg/kg body weight; Sigma). At day 16, blood glucose levels were measured, and mice with blood glucose >250 mg/dl were selected for continuation of their pregnancy. Following birth, blood glucose levels and body weights of newborn mice of diabetic and nondiabetic mothers were determined, and their kidneys were harvested.

Suppression Subtractive Hybridization-PCR-- Total RNA was extracted from newborn kidneys of mouse by the acid guanidinium isothiocyanate-phenol-chloroform extraction method as described previously (11), and poly(A+) mRNA was isolated by employing a Oligotex mRNA kit (Qiagen Co.). First strand and second strand cDNA synthesis, RsaI endonuclease enzyme digestion, adapter ligation, hybridization, and PCR amplification were preformed as described in the PCR-select cDNA subtraction manual (CLONTECH; Ref. 11). The differential PCR products in "tester" cDNA population subtracted from the "driver" were cloned into pCR II vector, sequenced, and subjected to a homology search by using BLAST program (www.ncbi.nlm.nih.gov/BLAST/).

Northern Blot Analyses-- Total RNA was isolated from kidneys of diabetic and control newborn mice and was subjected to 1.5% agarose gel electrophoresis containing 2.2 M formaldehyde and capillary-transferred onto Hybond N+ nylon membranes (Amersham Biosciences). The prehybridization and hybridization were performed with various [32P]dCTP-labeled (1 × 106 cpm/ml) partial length cDNA fragments derived from SSH-PCR (11). In addition, the total RNA was isolated from kidneys of newborn diabetic mice with different glucose levels in a range from 125 mg/dl to 450 mg/dl, and UbA52 mRNA expression was evaluated by Northern blot using mouse UbA52 cDNA probe.

Isolation of the Fusion Protein and Characterization of the Antibody-- By Northern blot analyses several up-regulated genes were identified. Among these, some as Rap1b, renal-specific oxido-reductase and Tim44 have been previously investigated with respect to diabetic pathobiology (11-13), whereas for others, e.g. UbA52, limited information is available in the literature. Thus, the relevance of UbA52 to diabetic nephropathy was investigated in the present study. Initially, full-length mouse UbA52 cDNA was generated by rapid amplification of cDNA ends-PCR and cloned into PCR II cloning vector (Invitrogen) and designated PCR II/UbA52cDNA. Two expression constructs were generated by PCR using PCR II/UbA52cDNA as template. First, the NdeI (CATATG) and BamHI (GGATCC) sites were introduced using sense (5'-GGG GGG CAT ATG ATC ATG CAG ATC TTC GTG AAG A-3') and antisense (5'-GGG GGG GGA TCC TTT GAC CTT CTT CTT GGG GC-3') primers. The PCR products were cloned into PCR II vector and then subcloned into NdeI- and BamHI-digested pET15b plasmid vector (Novagen Co.). The expression constructs, designated pET15b/UbA52, were sequenced. Transformation was performed using bacterial host BL21(DE3) (Novagen Co.). Two individual colonies were picked for generation of fusion protein. The purity of the isolated protein was assessed by SDS-PAGE analysis. Polyclonal antibodies were raised in rabbits, and IgG-enriched fractions were prepared by ammonium sulfate precipitation. Specificity of the antibody was determined by Western blot analysis. The preparation of plasmids, fusion proteins, and antibodies and Western blot analysis are detailed in previous publications (11-14).

Tissue Expression Studies-- For localization of UbA52 in the kidney, in situ hybridization and immunofluorescence studies were performed as described previously (12). For in situ hybridization, 3-µm-thick sections of paraffin-embedded kidney tissues of newborn old diabetic and nondiabetic control mice were prepared. They were deparaffinized, hydrated, and treated with proteinase K. This was followed by prehybridization and hybridization with 35[S]UTP-labeled UbA52 antisense riboprobes, which were generated with a Riboprobe in Vitro Transcription SystemTM (Promega). the tissue slides were coated with NTB2 photographic emulsion (Kodak), and the autoradiograms were prepared after 3 weeks of exposure. The control included tissues hybridized with sense riboprobes. For immunofluorescence microscopy, 4-µm-thick cryostat sections were prepared from kidneys of 3-week-old mice as well. The tissue sections were incubated with rabbit polyclonal anti-UbA52 antibody followed by a second incubation with fluorescein isothiocyanate-conjugated goat anti-rabbit IgG antibody. The sections were then examined with a UV microscope.

Effect of High Glucose on UbA52 Expression in Madin-Darby Canine Kidney Cells-- Madin-Darby canine kidney (MDCK) cells (ATCC), a well differentiated renal tubular epithelial cell line, was used for further studies, and expression of UbA52 was examined in high glucose ambience. The MDCK cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Hyclone Labs), 100 units/ml penicillin, 100 units/ml streptomycin (Invitrogen) in an atmosphere of 5% CO2 and 95% air at 37 °C. At the cell confluency of 70-80%, the concentration of fetal bovine serum was reduced to 0.5%. The concentration of D-glucose in the medium was adjusted to 5-30 mM, and the cultures were maintained for 24 h. L-Glucose (30 mM) was used as control. The cells were then collected and processed for UbA52 mRNA and protein expression studies.

For mRNA expression studies, competitive RT-PCR was utilized. First, a UbA52 competitive PCR template was constructed by using sense (5'-AGA TCT TCG TGA AGA CCC TGA CGA CGA CAT GGA GAA GAT CTG G-3') and antisense primers (5'-GGA AGG GGA CTT TAT TTG GTG AGG ATG CGG CAG TGG CCA T-3'). These primers included UbA52 and beta -actin sequences. Using these primers and a "mini gene construct" prepared previously (14) (GenBankTM accession number U17140) as the target DNA, a PCR product was generated, which was cloned into plasmid pCR II vector and designated the competitive PCR template. Using this competitive mutant plasmid DNA, the expected sizes of the PCR products for UbA52 and beta -actin were 317 and 274 bp, respectively. Whereas in wild type cDNA, the expected respective sizes of the PCR products were 434 and 430 bp. For quantitative competitive PCR, aliquots of first strand cDNA, synthesized from RNA of MDCK cells treated with various concentrations of glucose, were mixed with serial dilutions of competitive DNA and co-amplified in the presence of either beta -actin- or UbA52-specific primer in a PCR mixture as described previously (14). The PCR products were analyzed by 1.5% agarose gel electrophoreses.

For protein expression studies, immunoprecipitation procedures and Western blot analyses were employed, as detailed previously (11, 12). Briefly, the protein expression was determined in the whole cell lysate as well as in the ribosomal fractions. The MDCK cells treated with various concentrations of D-glucose were lysed with radioimmune precipitation buffer. The insoluble material was removed by centrifugation at 10,000 × g, and the protein concentration in the supernatant was determined by Bradford assay and adjusted to 1 mg/ml. About 500 µl of the supernatant was mixed with polyclonal anti-UbA52 with gentle agitation at 4 °C for 2 h, followed by the addition of 40 µl of 50% protein A-Sepharose 4B (Amersham Biosciences), and incubation was extended for another 1 h at 4 °C. The protein A-Sepharose beads were then washed with radioimmune precipitation buffer. About 30 µl of 2× SDS sample buffer was added to the washed beads, boiled for 5 min, and subjected to 12.5% SDS-PAGE. The gel proteins were transferred onto Nylon membranes, which were then incubated with rabbit anti-UbA52 polyclonal antibody followed by a second incubation with anti-rabbit IgG conjugated with horseradish peroxidase, and then autoradiograms were prepared by using the ECL detection system (Amersham Biosciences)

Because UbA52 is a protein that is fused with 60 S ribosome, its expression in the ribrosomal fraction was assessed in MDCK cells treated with various concentrations of D-glucose. The ribosomes were prepared following the method of Sherton and Wool (15). The ribosomal proteins were extracted from the ribosomes and subjected to immunoprecipitation procedures and Western blot analyses as described above.

Cloning of Mouse UbA52 Genomic DNA-- Mouse genomic UbA52DNA was isolated and cloned in two steps. First, 5'-flanking region of the mouse UbA52 gene was isolated using the mouse GenomeWalker kit (CLONTECH) following the vendor's instructions. Utilizing gene-specific antisense primer Ub-G1(AS) (5'-ATG GTG TCA CTG GGC TCG ACC TCA AGA GT-3'), a nested primer UbG1N(AS) (5'-GAT GGT CTT GCC CGT CAG GGT CTT-3'), and the PvuII DNA library of the kit, a PCR product of ~1 kb was generated, sequenced, cloned into pCR II vector, and designated pCRII/UbA52cDNA. This PCR product included the 5'-flanking region upstream of the open reading frame and the initiation ATG codon. In the second step, PCRs were carried out to isolate the remaining 3' end of the UbA52 gene. Using the mouse genomic 129 SvJ DNA (Jackson Laboratories), Ub-C(SE) sense (5'-CAG ACG CCA ACA TGC AGA TCT TCG TG-3'), and Ub-C(AS) antisense (5'-ACC ACA GCT TTA TTT GAC CTT CTT CTT GG-3') primers, a PCR product of ~0.4 kb was generated, which represented the 3' end of the ~1.4-kb UbA52 gene. The PCR product was cloned, sequenced, and analyzed for various motifs using the NCBI web site (www.motif.genome.ad.jp/MOTIF.html).

Primer Extension Analysis-- To determine the transcription start site(s) of the mouse UbA52, a primer extension reaction was carried out. The total RNA was extracted from mouse kidney, and after determining its integrity, mRNA was isolated (11). An antisense primer (UB-G1N (AS), 5'-GAT GGT CTT GCC CGT CAG GGT CTT-3'), the sequence of which was derived from downstream of the 5' end of open reading frame of UbA52, was synthesized. The primer (10 rho mol/µl) was labeled with [gamma -32P]dATP (3,000 Ci/mmol; Amersham Biosciences) and purified by ethanol precipitation. After annealing the radiolabeled primer (~10,000 dpm) with mRNA (0.5 µg) at 58 °C for 20 min, the extension reaction was carried out at 42 °C for 30 min using 1 unit of avian myeloblastosis virus-reverse transcriptase (Promega) in a reaction buffer containing 2 mM dNTP and dithiothreitol in a total volume of 20 µl. The reaction products were separated by 8% PAGE under denaturing conditions, and autoradiograms were prepared. Various primer extension reaction products were eluted from the gel, purified, cloned into pCR II vector, and then sequenced.

UbA52 Gene Promoter Analyses-- To identify the minimal promoter region and to understand the mechanism of glucose-induced up-regulation of UbA52, a GreatEscApeTM SEAP system (CLONTECH) and various deletion constructs were employed. For generation of deletion constructs, first, five sense Ub-G1(SE) (5'-GGG CTC GAG TCG ACG GCC CGG GCT GGT-3'), Ub-G2(SE) (5'-GGG CTC GAG ATG CAA CTA GAG ACA CAA GCT C-3'), Ub-G3(SE) (5'-GGG CTC GAG TGT ATT TGC CAG GCA CTG GC-3'), Ub-G4(SE) (5'-GGG CTC GAG GCC TGG ATA GAG TCA TCT G-3'), and Ub-G5(SE) (5'-GGG CTC GAG TTG AGC CTT GAT CAG AAC CT-3') and an antisense Ub-G1(AS) (5'-5'-GGG AAG CTT ATG GTG TCA CTG GGC TCG ACC TCA AGA GT-3') primers were synthesized. XhoI (CTC GAG) and HindIII (AAG CTT) sites were included in the sense and antisense primers, respectively. These sites are underlined in the various primer sequences. Using these primers and pCR II/UbA52gDNA (see above), various PCR products were generated and cloned into XhoI- and HindIII-digested pSEAP2-Enhancer plasmid vector (CLONTECH) and sequenced. COS7 cells (a cell line derived from African monkey kidney; ATCC) were transfected with various plasmid deletion constructs using LipofectAMINETM 2000 reagent, and the minimal promoter activity of the UbA52 gene was measured using a GreatEscAPeTM SEAP fluorescence detection kit (CLONTECH) in the supernatant of the cell cultures. The activities of various deletion constructs were expressed as the percentages of the activity in the deletion construct with the highest promoter activity, which was designated as being 100%.

Mutation Analysis and Dose-dependent Effect of Glucose on Promoter Activity-- The promoter analysis (see above) indicated that the highest activity was confined to deletion construct 5 (DC5 -198, +68 bp to -198 bp). Thus, this construct was used to assess the dose-dependent effect of glucose (5-30 mM) on the promoter activity and for the mutational analysis experiments. The SEAP activity of culture supernatants was determined as described above. Next, promoter activity was assessed after creating mutations in the motifs that are relevant to the glucose regulation. The two motifs that were present in the mouse UbA52 promoter and may be involved in the glucose regulation included E-box (CAGCTG, -129 bp to -134 bp) and putative stress response element (STRE; CCCCT, -154 bp to -158 bp). Three mutant plasmids were constructed by using a QuikChange site-directed mutagenesis kit (Stratagene). For E-box MUT1, the CAGCTG motif was changed to CAGTTG; for E-box MUT2, CAGCTG was changed to TGGCTG; and for STRE, CCCCT was changed to CATCT. After confirming the sequence of mutant plasmids, they were then transfected into COS7 cells as described above, and the promoter activity was determined in cells exposed to either 5 or 15 mM glucose for 48 h.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Isolation and Characterization of Differentially Expressed Genes in Streptozotocin-induced Diabetic Mouse Newborn Kidney-- The respective glucose levels of diabetic newborn versus control mice were: 421 ± 29 versus 121 ± 12 mg/dl (n = 50), respectively. Their respective body weights were: 0.58 ± 0.05 versus 1.3 ± 0.07 grams. The SSH-PCR followed by Northern blot analyses revealed nine different cDNA fragments with up-regulated gene expression to varying degrees in the hyperglycemic state (Fig. 1). Nucleotide sequence analysis of cDNAs indicated that all of them are known genes as follows: UbA52 (clone 1), heat shock protein 70 (clone 2), lactate dehydrogenase (clone 3), Rap1b (clone 4), nuclear ribonucleoprotein (clone 5), ferritin L subunit (clone 6), Na,K-ATPase (clone 7), renal specific oxido-reductase (clone 8), and inner mitochondrial membrane (Tim44) (clone 9). Among all these genes, the up-regulation in the mRNA expression of nuclear ribonucleoprotein (clone 5) was only minimal in the hyperglycemic state. Because SSH-PCR analysis revealed that UbA52 is up-regulated in hyperglycemic state, considerations were given to study the mechanisms involved in the up-regulation of UbA52 by glucose.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 1.   Northern blot analyses of differentially expressed genes in kidneys of normal and diabetic mice. Nine cDNA fragments were isolated by SSH-PCR and used as hybridization probes for Northern blot analysis of RNAs isolated from normal (N) and diabetic (D) newborn mice. Column 1, ubiquitin, Ub/60S (transcript sizes, ~2.8, ~1.7, and ~0.7 kb); column 2, heat shock protein 70, Hsp (transcript size, ~2.7 kb); column 3, lactate dehydrogenase, LDH (transcript size, ~1.7 kb); column 4, Rap1b (transcript size, ~2.3 kb); column 5, nuclear ribonucleoprotein, Nu-Rb (transcript size, ~1.4 kb); column 6, ferritin-L subunit, Ferritin (transcript size, ~1.2 kb); column 7, Na,K-ATPase, ATPase (transcript size, ~4.0 kb); column 8, renal-specific oxido-reductase, RSOR (transcript size, ~1.5 kb); column 9, inner mitochondrial membrane, Tim44 (transcript size, ~2.0 kb); column 10, beta -actin (transcript size, ~2.2 kb, control).

Relationship of UbA52 mRNA Expression with Hyperglycemia-- To investigate a possible relationship between the degree of hyperglycemia and renal UbA52 mRNA expression, Northern blot analyses were performed on the kidneys of newborn mice with different blood glucose levels. Four transcripts of ~0.7, ~1.7, ~2.8, and ~4.5 kb were detected under basal conditions, i.e. mice with a blood glucose level of 125 mg/dl. Their sizes corresponded to known sizes of transcripts of UbA52 (0.7 kb), ubiquitin B (1.7 kb), and ubiquitin C (4.5 and 2.8 kb) genes (Fig. 2A, lane 1). Their expression increased proportionally to the blood glucose levels (Fig. 2A, lanes 2-4) and a ~5-fold increase in expression in diabetic mice with a blood glucose levels of 450 mg/dl, suggesting a relationship between hyperglycemia and renal ubiquitin expression in the diabetic mice kidneys. No change in the beta -actin expression was observed (Fig. 2C).


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2.   Relationship between renal UbA52 mRNA expression and blood glucose levels. Northern blot analysis of kidneys from newborn mice with a blood glucose of 125 mg/dl (lane 1) shows four different sized transcripts representing UbA52 (0.7 kb), ubiquitin B (1.7 kb), and ubiquitin C (4.5 and 2.8 kb). In diabetic mice, renal ubiquitin mRNA expression increases proportionally to the blood glucose levels (A, lanes 2-4). The kidneys of mice with a blood glucose level of 450 mg/dl (lane 4) have a more than 5-fold UbA52 mRNA expression compared with those with a blood glucose of 125 mg/dl. mRNA expression of beta -actin is unaffected by the blood glucose levels (C). B depicts the quality and equal loading of total RNA in various lanes as indicated by the 28 and 18 S bands.

Characterization of Its Recombinant Protein and Kidney Expression-- A high level of protein expression was observed in Escherichia coli BL21(DE3) cells that were transfected with pET15b/UbA52 plasmid when induced with 1 mM of isopropyl-1-thio-beta -D-galactopyranoside. Multiple bands were observed in total cell lysate subjected to SDS-PAGE, and a prominent band of ~17 kDa was observed as well (Fig. 3A, CLONE.1 and CLONE.2). This band was not visualized when vector alone was used for transformation (Fig. 3A, VECTOR). Following the purification of proteins in the lysate by nickel column chromatography, a single band of ~17 kDa was observed (Fig. 3B, CLONE.1 and CLONE.2). The excess ~2 kDa of mass is presumably derived from the His6 tag. The fusion protein was used for generation of a rabbit polyclonal antibody, and its authenticity was confirmed by Western blot analysis. A major band of ~17 kDa was observed for the recombinant protein generated from two different cDNA clones (Fig. 3C, CLONE.1 and CLONE.2), suggesting that the antibody is specific for the UbA52 fusion protein.


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 3.   SDS-PAGE analysis of recombinant N-His6-UbA52 fusion protein. Several bands are present in the lysates of two different cDNA clones (A, CLONE.1 and CLONE.2) after isopropyl-1-thio-beta -D-galactopyranoside induction. In addition, a ~17-kDa prominent band is seen in the E. coli cell lysates. Purification of cell lysates by nickel affinity chromatography revealed a single major band of ~17 kDa (B, CLONE.1 and CLONE.2). The Western blot analysis confirmed the identity of the recombinant proteins of these two clones to be the UbA52 fusion protein (C).

Tissue Expression of UbA52 in Kidneys of Streptozotocin-induced Diabetic Mice-- In vivo expression of UbA52 in the kidney of diabetic mice was evaluated by in situ hybridization and immunohistochemistry. Although the kidneys of nondiabetic control animals showed a restricted hybridization signal to mid-cortical renal tubules (Fig. 4, A and B), UbA52 mRNA expression in diabetic newborn mice kidneys increased notably and was seen throughout the cortex (Fig. 4, E and F). Immunofluorescence studies revealed a parallel increase of UbA52 protein expression in the renal tubules of diabetic mice (Fig. 4, G and H) compared with control (Fig. 4, C and D). The UbA52 expression was not observed in glomeruli and medullary tubules.


View larger version (118K):
[in this window]
[in a new window]
 
Fig. 4.   mRNA and protein expression of UbA52 in kidneys of diabetic mice. In situ hybridization studies reveal UbA52 mRNA expression in the cortical tubules of newborn normoglycemic mice (A and B), and the mRNA expression is notably increased in diabetic mice (E and F). Immunofluorescence microscopy reveals UbA52 protein expression in renal tubules in the mid cortex (C and D). A parallel notable increase in the UbA52 expression is observed throughout the cortex in diabetic mice (G and H). No expression is observed in the renal glomeruli and medullary tubules.

UbA52 Expression in MDCK under High Glucose Stimulation-- To assess whether the high glucose ambience can directly affect the UbA52 expression, MDCK cells were exposed to high glucose, and UbA52 mRNA and protein expression was determined. The mRNA expression was assessed by competitive RT-PCR. The quantitative RT-PCR analysis revealed a linearity in the ratios of PCR products of wild type UbA52 cDNA to competitive plasmid DNA when plotted against 10-1-10-7 serial logarithmic dilutions of the competitive plasmid DNA, as described previously (14). For beta -actin control, a ratio of one was obtained at dilutions of 10-3-10-4 of the competitive plasmid DNA (Fig. 5A). This ratio was similar for cDNA prepared from MDCK cells exposed to 30 mM glucose (Fig. 5B), indicating no change in the beta -actin mRNA expression in high glucose ambience. For UbA52 control (5 mM D-glucose or 30 mM L-glucose), a ratio of 1 was obtained at dilutions of 10-4-10-5 of the competitive plasmid DNA (Fig. 5C), although for cDNA prepared from MDCK cells exposed to 30 mM glucose the ratio of 1 was obtained at 10-3-10-4 dilutions of the competitive DNA (Fig. 5D), suggesting a 10-100-fold increase in the UbA52 mRNA population in high glucose ambience. Next, the UbA52 protein expression was assessed in the MDCK whole cell lysate and ribosomal fractions. Immunoprecipitation and Western blot analysis of the whole cell lysate revealed a smear of ubiquitinated proteins ranging from ~25 to ~100 kDa. Also, a distinct band of ~16 kDa, corresponding to the molecular mass of UbA52 protein, was observed (Fig. 5E). The intensity of the smeared band was increased to a mild degree for the MDCK cells exposed to 30 mM compared with the control. However, the intensity of the ~16-kDa band was distinctly increased and was ~5-fold higher in cells exposed to high glucose ambience compared with the control. Immunoprecipitation and Western blot analyses of ribosomal fractions prepared from the MDCK cells exposed to normal and high glucose ambience revealed similar results, as observed with the whole lysate (Fig. 5F). The intensity of ~16-kDa band in ribosomal fraction was ~10-fold higher in MDCK exposed to 30 mM glucose compared with the control.


View larger version (81K):
[in this window]
[in a new window]
 
Fig. 5.   Expression of UbA52 in MDCK cells cultured in high glucose medium. A-D, competitive RT-PCR analysis of beta -actin (A and B) and UbA52 (C and D) in MDCK cells treated with 5 mM D-glucose or 30 mM L-glucose (B and D) and 30 mM D-glucose (C and E). Serial logarithmic dilutions of mutant competitive DNA template of UbA52 and beta -actin were co-amplified with a fixed amount of first-strand cDNA prepared from control and high glucose-treated MDCK cells. For beta -actin, no significant differences in the amplification of the wild type cDNA versus competitive plasmid DNA is observed between the control and high glucose-treated cells (A versus B), and the ratio of 1 is confined to the 10-3-10-4 log dilutions of the competitive DNA. For UbA52, an increase in the amplification of wild type cDNA versus competitive plasmid DNA is observed between control and high glucose-treated cells (C versus D) when plotted against the log dilutions of the competitive DNA, and the ratio of 1 shifted from 10-4-10-5 to 10-3-10-4. E, immunoprecipitation and Western blot analyses showing a significant increase in the expression of UbA52 (~16-kDa band indicated by arrow) in the whole cell lysate of cells exposed to 30 mM of glucose. Similarly, a mild increase is seen in the other ubiquitinylated proteins that are represented in the smeared 25-100 kDa band. F, immunoprecipitation and Western blot analysis of ribosomal fraction of MDCK cells treated with 5 mM (CONTROL) and 30 mM glucose, a major band of ~16 kDa is seen in ribosomal fraction, and its expression increased when MDCK cells were exposed to 30 mM glucose.

Characterization of Mouse UbA52 Gene and Mapping of the Transcription Initiation Site-- Using the PvuII mouse DNA library provided in the GenomeWalker kit and PCR, a 1289-bp genomic DNA product was obtained, and it contained a 891-bp stretch of 5'-untranslated region and a 384-bp segment of the translated region of the UbA52 gene (Fig. 6A). The 5'-untranslated region had no homology with the human UbA52 gene. Analysis of the 5'-untranslated promoter region of UbA52 revealed several consensus sequences and binding sites including SP1, AP-1, AP-2, TATA box, NF-kappa B, GC box elements, glucose response-related E-box sequences (CAGCTG), and STREs (CCCCT). Another E-box with a palindromic consensus sequence (CAGGTA) with a 4 out 6 match was present 6 nucleotides apart. The total stretch of 18 nucleotides included the E-boxes spanning from -117 to -134 bp. Other motifs included GATA-binding factor 2, heat shock factor, CCAAT/enhancer-binding protein, Ras-responsive element-binding protein, and Octamer factor-1 (Fig. 6A). Interestingly, by comparing the cDNA and genomic DNA sequences of mouse UbA52, no introns were found in the 5'-flanking region or within the coding segments of the gene (Fig. 6A).


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 6.   Nucleotide sequence analyses of genomic DNA of mice UbA52 gene. A, nucleotide sequence of the mouse UbA52 genomic DNA. The base pairs downstream from the initiation ATG codon of UbA52 are given as positive numbers. The base pairs upstream of ATG codon are labeled as negative numbers. The mouse UbA52 cDNA sequence is included as the second line under the genomic DNA sequence starting from the -041 nucleotide extending into the poly(A+) tail. The comparison of the cDNA and genomic sequences indicates that there are no introns upstream or within the coding region of the mouse UbA52 gene, which is in contrast to human UbA52 gene. Further analysis of the 5'-untranslated region indicated the presence of several motifs and response elements, which are underlined. The important motifs include those of STRE (CCCCT) and of the E-boxes (CAGCTG and CAGGTA). The two palindromic E-boxes are spaced apart by 6 nucleotides and stretch from -117 to -134 bp. The STRE motif is located 18 bp upstream of the first E-box. The TATA box (rectangular box) is present upstream of the transcription site. Open reading frames (ORF(1) and ORF(2)) are indicated by two angled arrows. The termination codon is indicated by an octagon. GATA-2, GATA-binding factor 2; HSF, heat shock factor; C/EBP, CCAAT/enhancer-binding protein; RREB-1, Ras-responsive element-binding protein; Oct-1, Octamer factor-1. B, primary extension analysis showing three transcription start sites (arrowheads) similar to that of the human UbA52 gene. Among the three extension products, the middle one of 62 bp yielded a distinct band, and its nucleotide sequence (CGGCCG) is similar to that indicated above (inset). C, the nucleotide sequence of the putative transcription start site (CGGCCG) of mouse UbA52 gene is similar that of the human. However, it is located -959 bp upstream from the initiation ATG codon in human. Also, the mouse UbA52 lacked the 940-bp intronic segment upstream of the 5'-flanking region.

Primer extension analysis revealed three extension products when Ub-G1N(AS) primer and mouse total RNA or mRNA were used (Fig. 6B). No extension product was observed when tRNA was used. The control RNA provided in the kit revealed an expected 87-bp primary extension reaction product. Among the three extension products, the middle one of 62 bp yielded a distinct band, the analysis of which revealed a major putative transcription start site with the CGGCCG sequence (Fig. 6B, inset). It was located at -22 bp from the ATG initiation codon and -200 bp downstream of the TATA box (Fig. 6, A and C). The transcription start site sequence (CGGCCG) of the mouse UbA52 gene was similar to that of humans, but in the latter it was located -959 bp upstream from the initiation ATG codon (Fig. 6C).

Promoter Activity Analysis-- To identify the minimal promoter region that regulates the constitutive expression of the mouse UbA52 gene, a series of deletion constructs were generated and designated DC1 -891, DC2 -741, DC3 -592, DC4 -359, and DC5 -198 (Fig. 7). The highest SEAP activity was observed in DC5 -198, which included sequences -198 bp of 5'-flanking region +68 bp from the initiation ATG codon. The activity was about ~32 times that of basic pSEAP vector with no insert. Because the highest basal promoter activity was confined in DC5 -198 bp that contains STRE and glucose response-related E-box sequences, this construct was used to assay the SEAP activity under different concentrations of glucose ranging from 0 to 30 mM. A dose-dependent increase in the SEAP activity was observed (Fig. 8), and the maximal activity was observed at 15 mM glucose concentration. The latter concentration was used for the mutational analysis of the UbA52 promoter.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7.   Promoter analysis of mouse UbA52 gene. Schematic representation of mouse SEAP activity of UbA52 promoter (bar graphs) corresponding to reporter gene constructs with sequential deletions are given on the left side of the diagram. Five deletion constructs of pESAP2-enhancr/UbA52 promoter were generated by PCR using sense and antisense primers. 48 h after transfection with the constructs into COS7 cells, the media were collected to measure the SEAP activity. The control included the pSEAP2-basic vector, which contained neither SV40 enhancer nor promoter. The highest enzyme activity of SEAP is seen in the DC5 -198 deletion construct, and it is ~32 times higher than that of the pSEAP2-basic vector. The activity in this construct is significantly higher than other deletion constructs. *, p < 0.01. The data are presented as the means ± S.D. (n = 4).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of various concentrations of glucose on the SEAP activity and mutation analysis of STRE and E-box. The SEAP activities in COS7 cells transfected with DC5 -198 plasmid are given as bar graphs with the means ± S.D. (n = 4). The highest activity is seen at 15 mM glucose concentration in medium. The experiments were performed in quadruplicate. The mutation in the STRE element (CCCCT to CATsCT) resulted in a substantial decrease in the SEAP activity. Similarly, the MUT2 mutation in the E-box (CAGCTG to TGGCTG) resulted in a significant decrease in the SEAP activity. *, p < 0.01. However, the MUT1 mutation in the E-box (CAGCTG to CAGTTG) did not cause any significant change in the SEAP activity. WT, wild type.

As indicated above, the DC5 -198 deletion construct included STRE (CCCCT) and glucose response-related E-box sequences (CAGCTG); thus, mutations were created in these motifs (Fig. 8). The mutant plasmids were transfected into COS7 cells, and the SEAP activity was determined under 5 and 15 mM glucose concentrations in the medium. Mutation in the STRE motif (CCCCT to CATCT) induced a remarkable decrease in the SEAP activity at 15 mM glucose concentration compared with the basal activity of the promoter. Mutation in the first E-box (MUT1, CAGCTG to CAGTTG) did not result any significant change in the SEAP activity compared with the basal promoter activity. However another mutation in the first E-box (MUT2, CAGCTG to TGGCTG) resulted in a notable decrease in the SEAP activity (Fig. 8). These findings suggest that both of these motifs are involved in the up-regulation of UbA52 in high glucose ambience.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Diabetic nephropathy plays an important role in the development of end stage renal disease. However, pathophysiologic mechanisms are still incompletely understood. At the molecular level, several genes and their functions in diabetic nephropathy have been characterized, whereas others remain to be discovered. So far, during the last decade, various techniques that are modifications of the original method of differential display have been used to identify the glucose-regulated genes in different organ systems affected by diabetes mellitus. The cells or organs investigated by the use of such modified methods include retinal pericytes, aortic smooth muscle cells, cardiac myocytes, and the kidney (8, 11, 16). Lately, to study the gene regulation in diabetic nephropathy, we have successfully employed a versatile technique, SSH-PCR, yielding <10% spurious signals, and a number of differentially expressed genes have been identified. The current study extends the exploration of the genes that are relevant to diabetic nephropathy, and several genes exhibiting a transcriptional response to hyperglycemia are described in this paper (Fig. 1). Some of them (i.e. Rap1b, a small G-protein; RSOR, a renal specific oxido-reductase; and Tim44, an inner mitochondrial membrane translocase) have been described in our previous publications (11-13). Interestingly, these genes and the other genes identified in this study, like UbA52, are transcriptionally responsive to various forms of stresses, including oxidant and carbonyl stresses. Both of these stresses are relevant to the pathobiology of diabetic nephropathy and apoptosis, as recently alluded to by Brownlee (17). The isolation of genes responsive to a common transcriptional stimulus, i.e. hyperglycemia, with the use of SSH-PCR underscores its utility in the exploration of differential gene regulation. In this investigation, we focus on the biology of the ubiquitin fusion protein UbA52 with regard to its relevance to diabetic nephropathy.

About 20 years ago, a protein that promoted the differentiation of lymphocytes was isolated, and it is now known as ubiquitin (9). The ubiquitin gene typically exists in two states. First, as a doublet, e.g. ubiquitin B, or linear repeats in a polyubiquitin chain, i.e. ubiquitin C; second, the ubiquitin gene may be fused to ribosomal proteins, i.e. UbA52 and UbA80 (9, 18, 19). Although ubiquitin has no intrinsic proteolytic activity, it plays an important role in the turnover of cellular proteins by closely regulating their degradation. The latter is a multistep ATP-dependent pathway that involves the activation of carboxyl terminus of ubiquitin, its conjugation with a specific protein, and the addition of ubiquitins to form polyubiquitin, which is then followed by degradation of ubiquitin-tagged protein in 26S proteasome with the release of peptide fragments of the protein and ubiquitin to be reutilized (9, 19). The ubiquitin-dependent proteolysis is responsive to the stimuli of a diverse group of molecules, including glucocorticoids and an inhibitor of NF-kappa B, Ikappa B (20), suggesting that the ubiquitin-dependent proteolytic pathway is relevant in various pathobiological processes. The NF-kappa B has an important role in cachexia, the state with skeletal muscle loss, and in support of the role of ubiquitin-proteasome pathway in muscle wasting in diabetes is the seminal work of Mitch and co-workers carried out during the last decade (10, 20, 21). These studies suggest that metabolic acidosis and glucocorticoids are the major contributors to ubiquitin-dependent muscle proteolysis in diabetes mellitus along with the increased transcription of ubiquitin. This catabolic state of muscle wasting seems to be the major phenotype in diabetes mellitus, even when there may an abundance of anabolic growth factors in circulation, like in this study where diabetic newborn mice exhibited a substantial loss of body weight (0.58 ± 0.05 g versus 1.3 ± 0.07 g).

In addition to the skeletal muscle, an increased transcription of ubiquitin in cardiac musculature has been reported in diabetes mellitus (22). Moreover, it seems that there is a systemic increase in gene transcription, because high blood levels of ubiquitin have been found, and they have inverse correlation with the decrease in the muscle action potential in diabetes mellitus (23). The above studies mainly address the pathobiology of ubiquitin, whereas the current observations describe the relevance of ubiquitin fusion protein, UbA52, in diabetes mellitus. Moreover, the increased transcription of UbA52 in the kidneys of diabetic mice and its renal mRNA expression rising proportionally to blood glucose levels of newborn diabetic mice (Fig. 2) relate to an important organ-specific complication of diabetes mellitus, i.e. diabetic nephropathy. Therefore, it should be noted that in previous studies a ubiquitin-like protein, unrelated to UbA52, was found to be differentially expressed in diabetic rats with hyperglycemia (16).

Aside from the above studies, there is no report available in the literature describing the distribution of UbA52 in the kidney. In the present study, we could show by in situ hybridization and immunofluorescence techniques using an antibody generated against its recombinant protein (Fig. 3) that in vivo expression of UbA52 is confined to the renal tubules (Fig. 4). Moreover, its mRNA and protein expression is notably up-regulated in the tubular compartment of the kidneys of diabetic mice. In context of tubular expression of ubiquitin ligase (24), Nedd4, a protein with WW domain and ligase activity (25), and ubiquitin-conjugating enzyme E2 (26), selective expression of UbA52 in the renal tubules would suggest that the ubiquitin-proteasome proteolytic system is indeed operative in this compartment of the kidney and might play an important role in diabetic nephropathy. To assess whether tubular cells are responsive to high glucose ambience directly, MDCK cells, a tubular epithelium-derived cell line, were employed. By RT-PCR analyses, a 10-100-fold increase in UbA52 mRNA expression was observed at 30 mM glucose in the culture medium (Fig. 5, A-D). In addition to the transcriptional effect on UbA52, increased translation reflected by the increased intensity of the ~16-kDa band in the cell lysates was also noted (Fig. 5E). In addition, increased intensity of the smeared band was observed, which may be due to the cross-reactivity of UbA52 antibody with other ubiquitinated proteins or polyubiquitin. Nevertheless, ~16-kDa band seems to correspond to the UbA52 ribosomal protein, because an identically sized band with increased intensity was observed in the ribosomal fraction of the glucose-treated MDCK cells (Fig. 5F). A similarly sized band, corresponding to UbA52 protein, has been observed in the ribosomal fractions prepared from various stages of development of Drosophila melanogaster (27). The presence of the single ~16-kDa band in our studies is intriguing, because usually during the proteolytic processing the co-synthesized ubiquitin is removed. It is conceivable that this band represents a protein that underwent post-translational conjugation of carboxyl extension protein 52 to ubiquitin.

The next question that needs to be addressed is the mechanism by which glucose increases the transcription of UbA52. It is known that insulinopenia accompanied with acidosis contributes to cachexia (28), although hyperinsulinemia and hyperaminoacidemia ameliorate the loss of skeletal mass and decrease the transcription of ubiquitin (29), indicating thereby that one needs to search for the promoter elements of the gene that could regulate insulin signaling, such as E-box (30). Another rationale to investigate the promoter analysis of UbA52 is based on the studies indicating that insulinopenia and glucocorticoids increase the transcription of ubiquitin C by involving Sp1 promoter site (31). The mouse UbA52 promoter has some of the transcription factors, such as Sp1, Ap1, and NF-kappa B, which are similar to those in the human homologue (32) and in ubiquitin C0 (33). Unlike the human UbA52 promoter that shares features of many of the ribosomal genes, the mouse UbA52 included canonical TATA box sequences and consensus sequences for STRE, E-box, and heat shock factor elements (Fig. 6A). The transcription start site sequence (CGGCCG) was similar, as assessed by primer extension analysis (Fig. 6B); however, unlike in human UbA2, the mouse UbA52 had no introns downstream of the transcription site (Fig. 6C). Interestingly, no introns were found in the coding region of the UbA52 gene, indicating that the whole mouse gene is made up of a single exon, unlike that of humans, which is made up of three exons (32). The mouse cDNA sequences in the open reading frame revealed 85% homology with human UbA52. Finally, the mouse UbA52 protein sequence was identical to that of the human and also of the UbA80 up to the 60th amino acid residue (34).

For identification of the minimal promoter region, deletion constructs of the 5'-flanking region of mouse UbA52 were prepared and transfected into COS7 cells (a cell line derived from kidney cells), and SEAP activity in the culture medium was determined (Fig. 7). Basal promoter activity was confined to the +68 to -198 bp, i.e. in the DC5 -198 construct. This segment included STRE (CCCCT) and two E-box (CAGCTG and CAGGTA) motifs that are known to be responsive to glucose. Among these two palindromic E-boxes, the first one has a perfect canonical CAGCTG sequence, whereas second one has an imperfect consensus sequence with a match of 4 of 6 nucleotides. Relative to the construct DC5 -198, 75% of the SEAP activity could be measured in the DC3 -592 construct, which may be partly attributed to the presence of additional STRE elements responsive to carbonyl stress (Fig. 7). With the use of the DC5 -198 construct, a dose-dependent increase in the SEAP activity was observed (Fig. 8), and like the promoter activity of glucagon receptor, the maximal activity was observed at a 15 mM concentration of glucose (35). This is intriguing because the maximal increase in the UbA52 mRNA expression is observed with 30 mM glucose in the mesangial cell culture.2 These differences may be attributed to a number of factors, including that the SEAP activity was determined in COS7 cells and that the expression of glucose transporters between these two cell lines may not be comparable.

The stretch spanning the two E-boxes is the major groove in the target DNA, and it serves as the contact site for the interaction between specific amino acids and the nucleotide bases. Such palindromic E-boxes have been reported in promoters of other genes that are transcriptionally regulated by high glucose ambience. They include pyruvate kinase L, Spot14 (a lipogenesis-associated protein), and glucagon receptor (35-37). They are expressed in the liver, the major site for the transcription regulation of glucose. In pyruvate kinase L and Spot14 gene, the E-box core motifs constitute the carbohydrate response elements and are known as GIRE and ChoRE, respectively (36, 37). The location of glucose regulatory elements containing the E-box motifs varies considerably among the three genes, e.g. from -144 to -168 nucleotides in pyruvate kinase L and from -1431 to -1448 nucleotides in Spot14, with an intermediate location for the glucagon receptor, i.e. from -527 to -545 bp. In the UbA52 the stretch of glucose regulatory elements containing E-boxes seems to be confined between -117 and -134 bp (Fig. 6A).

The presence of STRE and E-boxes in the mouse UbA52 gene led us to define their role in the transcriptional regulation of glucose. In the glucagon receptor gene, the two E-boxes with CACGTG and CAGCTG sequences are believed to be essential for promoter activity (35), because a mutation in the CAGCTG motif to CAGTTG results in a decrease in the activity of the reporter gene. Similar observations were made for the UbA52 gene, where a mutation in CAGCTG motif to TGGCTG resulted in a marked decrease in the reporter gene activity at 15 mM glucose concentration, suggesting a role for the E-box in the biology of UbA52 gene relevant to diabetes mellitus (Fig. 8). However, no change in the reporter activity was observed when mutation in the single base pair, i.e. CAGCTG to CAGTTG, was introduced. This may suggest that mutation in two contiguous base pairs or alternatively the purine base substitution is required to perturb the functions of E-box confined to the major groves in the target DNA. In addition to the E-box, mutational analyses were also carried for 18 bp upstream STRE (CCCCT) motif. Ubiquitin mRNA expression is a major stress-induced transcript in mammalian cells (38). Some of the physiologic and pathologic stresses that increase its expression include exercise, heat, ischemia, uncoupling of oxidative phosphorylation, alterations in pH, calcium and glucose metabolism, and reactive oxygen species-induced proteolysis (9, 10, 19). Given the fact that oxidant stress is believed to be a common denominator in the pathobiology of diabetes mellitus, the role of the STRE motif in the UbA52 reporter gene activity seemed worth investigating. Like in manganese superoxide dismutase gene (39), a mutation in CCCCT to CATCT in at 15 mM glucose concentration resulted in a marked suppression in UbA52 reporter gene activity (Fig. 8), suggesting a role for the STRE motif in the hyperglycemic state or in cells subjected to high glucose ambience.

In summary, the findings of this study indicate that the ubiquitin fusion protein UbA52 is another important molecule relevant to the pathobiology of diabetic nephropathy, and its transcription regulation is modulated by the characteristic elements embedded in its promoter region. It is anticipated that the observations made in this study give an impetus to search for novel UbA52-interacting molecules, the biology of which could further enhance our understanding of the pathogenesis of diabetic nephropathy.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK-28492 and DK-60635.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Dept. of Pathology, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611. Tel.: 312-503-0084; Fax: 312-503-0627; E-mail: y-kanwar@northwestern.edu.

Published, JBC Papers in Press, May 24, 2002, DOI 10.1074/jbc.M204665200

2 L. Sun, X. Pan, J. Wada, C. S. Haas, R. P. Wuthrich, F. R. Danesh, S. S. Chugh, and Y. S. Kanwar, unpublished results.

    ABBREVIATIONS

The abbreviations used are: SSH, subtraction suppression hybridization; MDCK, Madin-Darby canine kidney; RT, reverse transcription; SEAP, secreted alkaline phosphatase promoter; DC, deletion construct; STRE, stress response element.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Price, R. G., and Hudson, B. G. (1987) Renal Basement Membranes in Health and Disease , p. 439, Academic Press, Boston, MA
2. Voziyan, P. A., Metz, T. O., Baynes, J. W., and Hudson, B. G. (2002) J. Biol. Chem. 277, 3397-3403[Abstract/Free Full Text]
3. Feliers, D., Duraisamy, S., Faulkner, J. L., Duch, J., Lee, A. V., Abboud, H. E., Choudhury, G. G., and Kasinath, B. S. (2001) Kidney Int. 60, 495-504[CrossRef][Medline] [Order article via Infotrieve]
4. Gooch, J. L., Tang, Y., Ricono, J. M., and Abboud, H. E. (2001) J. Biol. Chem. 276, 42492-42500[Abstract/Free Full Text]
5. Reddy, M. A., Thimmalapura, P. R., Lanting, L., Nadler, J. L., Fatima, S., and Natarajan, R. (2002) J. Biol. Chem. 277, 9920-9928[Abstract/Free Full Text]
6. Natarajan, R., Gerrity, R. G., Gu, J. L., Lanting, L., Thomas, L., and Nadler, J. L. (2002) Diabetologia 45, 125-133[CrossRef][Medline] [Order article via Infotrieve]
7. Chen, S., Cohen, M. P., Lautenslager, G. T., Shearman, C. W., and Ziyadeh, F. N. (2001) Kidney Int. 59, 673-681[CrossRef][Medline] [Order article via Infotrieve]
8. Wada, J., Makino, H., and Kanwar, Y. S. (2002) Kidney Int. 61, 73-78[Medline] [Order article via Infotrieve]
9. Hershko, A., and Ciechanover, A. (1998) Annu. Rev. Biochem. 67, 425-479[CrossRef][Medline] [Order article via Infotrieve]
10. Mitch, W. E., and Goldberg, A. L. (1996) N. Engl. J. Med. 335, 1897-1905[Free Full Text]
11. Sun, L., Chugh, S., Pan, X. M., Wallner, E. I., Wada, J., and Kanwar, Y. S. (2001) Kidney Int. 60, 2129-2141[CrossRef][Medline] [Order article via Infotrieve]
12. Yang, Q., Dixit, B., Wada, J., Tian, Y., Wallner, E. I., Srivastava, S. K., and Kanwar, Y. S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 9896-9901[Abstract/Free Full Text]
13. Wada, J., and Kanwar, Y. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 144-149[Abstract/Free Full Text]
14. Kanwar, Y. S., Liu, Z. Z., Kumar, A., Usman, M. I., Wada, J., and Wallner, E. I. (1996) J. Clin. Invest. 98, 2478-2488[Medline] [Order article via Infotrieve]
15. Sherton, C. C., and Wool, I. G. (1971) Anal. Biochem. 41, 506-526
16. Page, R., Morris, C., Williams, J., von Ruhland, C., and Malik, A. N. (1997) Biochem. Biophys. Res. Commun. 232, 49-53[CrossRef][Medline] [Order article via Infotrieve]
17. Brownlee, M. (2001) Nature 414, 813-820[CrossRef][Medline] [Order article via Infotrieve]
18. Sun, L., and Wuthrich, R. P. (1999) Biochem. Genet. 7, 139-147[CrossRef]
19. Wilkinson, K. D. (1995) Annu. Rev. Nutr. 15, 161-189[CrossRef][Medline] [Order article via Infotrieve]
20. Du, J., Mitch, W. E., Wang, X., and Price, S. R. (2000) J. Biol. Chem. 275, 19661-19666[Abstract/Free Full Text]
21. Price, S. R., Bailey, J. L., Wang, X., Jurkovitz, C., England, B. K., Ding, X., Phillips, L. S., and Mitch, W. E. (1996) J. Clin. Invest. 98, 1703-1708[Medline] [Order article via Infotrieve]
22. Liu, Z., Miers, W. R., We, L., and Barrett, E. J. (2000) Biochem. Biophys. Res. Commun. 276, 1255-1260[CrossRef][Medline] [Order article via Infotrieve]
23. Akarsu, E., Pirim, I., Capoglu, I., Deniz, O., Akcay, G., and Unuvar, N. (2001) Diabetes Care 24, 100-103[Abstract/Free Full Text]
24. Sivaraman, L., Nawaz, Z., Medina, D., Conneely, O. M., and O'Malley, B. W. (2000) Breast Cancer Res. Treat. 62, 185-195[CrossRef][Medline] [Order article via Infotrieve]
25. Kamynina, E., Tauxe, C., and Staub, O. (2001) Am. J. Physiol. 281, F469-F477[Abstract/Free Full Text]
26. Wing, S. S., and Banville, D. (1994) Am. J. Physiol. 267, E39-E48[Abstract/Free Full Text]
27. Redman, K. L. (1994) Insect Biochem. Mol. Biol. 24, 191-201[CrossRef][Medline] [Order article via Infotrieve]
28. Mitch, W. E., Bailey, J. L., Wang, X., Jurkovitz, C., Newby, D., and Price, S. R. (1999) Am. J. Physiol. 276, C1132-C1138[Abstract/Free Full Text]
29. Larbaud, D., Debras, E., Taillandier, D., Samuels, S. E., Temparis, S., Champredon, G. J., and Attaix, D. (1996) Am. J. Physiol. 271, E505-E512[Abstract/Free Full Text]
30. Travers, M. T., Vallance, A. J., Gourlay, H. T., Gill, C. A., Klein, I., Bottema, C. B., and Barber, M. C. (2001) Biochem. J. 359, 273-284[CrossRef][Medline] [Order article via Infotrieve]
31. Marinovic, A. C., Mitch, W. E., and Price, S. R. (2000) J. Am. Soc. Nephrol. 11, 624 (abstr.)
32. Baker, R. T., and Board, P. G. (1991) Nucleic Acids Res. 19, 1035-1040[Abstract/Free Full Text]
33. Marinovic, A. C., Mitch, W. E., and Price, S. R. (2000) Biochem. Biophys. Res. Commun. 274, 537-541[CrossRef][Medline] [Order article via Infotrieve]
34. Kirschner, L. S., and Stratakis, C. A. (2000) Biochem. Biophys. Res. Commun. 270, 1106-1110[CrossRef][Medline] [Order article via Infotrieve]
35. Portois, L., Maget, B., Tastenoy, M., Perret, J., and Svoboda, M. (1999) J. Biol. Chem. 274, 8181-8190[Abstract/Free Full Text]
36. Hasegawa, J., Osatomi, K., Wu, R. F., and Uyeda, K. (1999) J. Biol. Chem. 274, 1100-1107[Abstract/Free Full Text]
37. Koo, S. H., and Towle, H. C. (2000) J. Biol. Chem. 275, 5200-5207[Abstract/Free Full Text]
38. Fornace, A. J., Alamo, I., Hollander, M. C., and Lamoreaux, E. (1989) Nucleic Acids Res. 17, 1215-1230[Abstract/Free Full Text]
39. Zahringer, H., Thevelein, J. M., and Nwaka, S. (2000) Mol. Microbiol. 35, 397-406[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Chem.Home page
H. Dihazi, G. A. Muller, S. Lindner, M. Meyer, A. R. Asif, M. Oellerich, and F. Strutz
Characterization of Diabetic Nephropathy by Urinary Proteomic Analysis: Identification of a Processed Ubiquitin Form as a Differentially Excreted Protein in Diabetic Nephropathy Patients
Clin. Chem., September 1, 2007; 53(9): 1636 - 1645.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Nayak, P. Xie, S. Akagi, Q. Yang, L. Sun, J. Wada, A. Thakur, F. R. Danesh, S. S. Chugh, and Y. S. Kanwar
Modulation of renal-specific oxidoreductase/myo-inositol oxygenase by high-glucose ambience
PNAS, December 13, 2005; 102(50): 17952 - 17957.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
K. G. Ewens, R. A. George, K. Sharma, F. N. Ziyadeh, and R. S. Spielman
Assessment of 115 Candidate Genes for Diabetic Nephropathy by Transmission/Disequilibrium Test
Diabetes, November 1, 2005; 54(11): 3305 - 3318.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/33/29953    most recent
M204665200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, L.
Right arrow Articles by Kanwar, Y. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, L.
Right arrow Articles by Kanwar, Y. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement